BioCentury | Jun 30, 2014
Company News

Core Diagnostics management update

Core Diagnostics Inc. , Palo Alto, Calif. Business: Diagnostic Hired: K. Balachandran as CEO, formerly COO of NeuroMetrix Inc. WIR Staff Diagnostic...
BioCentury | Jul 22, 2013
Company News

Quest Diagnostics, Royalty Pharma deal

Royalty Pharma acquired from diagnostic company Quest Diagnostics the rights to royalties for cancer compound ibrutinib for $485 million in cash. Quest said the deal is in line with its strategy announced last year to...
BioCentury | Mar 18, 2013
Company News

DiagnoCure, Signal Genetics deal

...GCC Colorectal Cancer Staging Test . DiagnoCure, which said Signal Genetics decided to exit the non-core diagnostics...
BioCentury | Mar 4, 2013
Company News

Quest Diagnostics, Radiometer Medical ApS deal

Quest Diagnostics will sell its HemoCue point-of-care diagnostic products business to Radiometer for about $300 million plus adjustments for cash balances. The deal is expected to close this month. In January, Quest said it planned...
BioCentury | Jan 21, 2013
Company News

Quest Diagnostics diagnostic news

Quest Diagnostics plans to sell its HemoCue point-of-care diagnostic products business as part of its ongoing strategy to refocus its core diagnostic information services business for physicians and hospitals. Quest did not disclose details. Last...
BioCentury | Jan 7, 2013
Company News

Access Genetics, Quest Diagnostics deal

On Dec. 31, 2012, Quest said it sold its OralDNA Labs salivary-diagnostics business to Access Genetics. Quest said the divestiture represents a step in the company's ongoing strategy to refocus its core diagnostic information services...
BioCentury | Aug 25, 2008
Company News

Abbott pharmaceuticals news

In an SEC filing, Abbott disclosed that it will restructure and reduce headcount by about 1,000 (1.5%) to 67,000 over three and a half years in its core diagnostic business to streamline global manufacturing, reduce...
Items per page:
1 - 7 of 7
BioCentury | Jun 30, 2014
Company News

Core Diagnostics management update

Core Diagnostics Inc. , Palo Alto, Calif. Business: Diagnostic Hired: K. Balachandran as CEO, formerly COO of NeuroMetrix Inc. WIR Staff Diagnostic...
BioCentury | Jul 22, 2013
Company News

Quest Diagnostics, Royalty Pharma deal

Royalty Pharma acquired from diagnostic company Quest Diagnostics the rights to royalties for cancer compound ibrutinib for $485 million in cash. Quest said the deal is in line with its strategy announced last year to...
BioCentury | Mar 18, 2013
Company News

DiagnoCure, Signal Genetics deal

...GCC Colorectal Cancer Staging Test . DiagnoCure, which said Signal Genetics decided to exit the non-core diagnostics...
BioCentury | Mar 4, 2013
Company News

Quest Diagnostics, Radiometer Medical ApS deal

Quest Diagnostics will sell its HemoCue point-of-care diagnostic products business to Radiometer for about $300 million plus adjustments for cash balances. The deal is expected to close this month. In January, Quest said it planned...
BioCentury | Jan 21, 2013
Company News

Quest Diagnostics diagnostic news

Quest Diagnostics plans to sell its HemoCue point-of-care diagnostic products business as part of its ongoing strategy to refocus its core diagnostic information services business for physicians and hospitals. Quest did not disclose details. Last...
BioCentury | Jan 7, 2013
Company News

Access Genetics, Quest Diagnostics deal

On Dec. 31, 2012, Quest said it sold its OralDNA Labs salivary-diagnostics business to Access Genetics. Quest said the divestiture represents a step in the company's ongoing strategy to refocus its core diagnostic information services...
BioCentury | Aug 25, 2008
Company News

Abbott pharmaceuticals news

In an SEC filing, Abbott disclosed that it will restructure and reduce headcount by about 1,000 (1.5%) to 67,000 over three and a half years in its core diagnostic business to streamline global manufacturing, reduce...
Items per page:
1 - 7 of 7